Celgene names exec to oversee mid-, late-stage development

Celgene Corp. has named Dr. Alise Reicin its president of global clinical development, it announced this week.

Reicin will take on her new post Nov. 1, and will be responsible for all aspects of mid- to late-stage clinical development across Summit-based Celgene’s portfolio. She will be part of the executive committee and report to Chairman and CEO Mark Alles.

“Dr. Reicin is an accomplished physician with an excellent record of developing important therapeutics for multiple cancer and inflammatory indications,” Alles said in a prepared statement. “Led by Alise, our clinical development organization will be structured to more completely align with our strategy and mission to discover, develop and commercialize innovative therapies for patients with unmet need.”

The appointment is part of Celgene’s strategy to strengthen the company for long-term success, further establishing clinical development work and enhancing strategic leadership in discovery, development and commercialization, the company said.

Dr. Rupert Vessey will continue to lead early-stage development as president, research & early development, and Dr. Jay Backstrom will continue to oversee global regulatory strategy, drug safety and more as chief medical officer, Celgene said.

Reicin most recently was senior vice president and head of global clinical development in research and development at EMD Serono, Merck’s biopharmaceutical business.